Stockscreener 앱 받기
16.80
2.50%
0.41
시장 영업 전:
16.29
-0.51
-3.04%
Neuropace Inc 주식(NPCE)의 최신 뉴스
Why NeuroPace Inc. stock remains undervalued2026 world cup usa national team round of 16 defensive leaders pressing system knockout prediction breakdown - ulpravda.ru
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
NeuroPace stock dips after pricing $65M share offering - MSN
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com
Published on: 2025-12-25 19:47:27 - moha.gov.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
How resilient is NeuroPace Inc. stock in market downturns2025 Market WrapUp & Long Hold Capital Preservation Tips - bolumsonucanavari.com
Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World
Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда
How NeuroPace Inc. stock performs in rate cut cycles2025 Earnings Impact & Weekly Watchlist for Consistent Profits - DonanımHaber
Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда
Can NeuroPace Inc. stock deliver sustainable ROEWatch List & Fast Entry and Exit Trade Plans - Улправда
Is NeuroPace Inc. stock oversold or undervaluedTrade Exit Report & Expert Curated Trade Ideas - DonanımHaber
Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Will NeuroPace Inc. stock benefit from green energy trendsWeekly Trade Report & Entry and Exit Point Strategies - DonanımHaber
Aug Rallies: Can NeuroPace Inc. stock deliver sustainable ROETrade Performance Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Lake Street Keeps Their Buy Rating on NeuroPace (NPCE) - The Globe and Mail
UBS Group Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - Defense World
NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment - Investing.com Nigeria
Is It Time To Consider Buying NeuroPace, Inc. (NASDAQ:NPCE)? - Yahoo Finance
NeuroPace Files FDA Application to Expand RNS System Use - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Investing News Network
Neuropace files PMA supplement to FDA - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS - Business Wire
UBS Maintains NeuroPace (NPCE) Buy Recommendation - Nasdaq
UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating - marketscreener.com
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00 - MarketBeat
Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00 at JPMorgan Chase & Co. - Defense World
NeuroPace price target raised to $20 from $18 at JPMorgan - MSN
Bank Watch: How buybacks impact NeuroPace Inc stock value2025 Biggest Moves & AI Forecast Swing Trade Picks - moha.gov.vn
JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - MSN
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com UK
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy By Investing.com - Investing.com South Africa
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace
Neuropace shows 77% reduction in seizures - BioWorld MedTech
NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com
NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada
Neuropace announces positive 18-month NAUTILUS trial results in idiopathic generalized epilepsy - marketscreener.com
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
Is NeuroPace Stock Built to Withstand a Pullback? - Trefis
MACD Signal: Will USCF ETF Trust USCF Sustainable stock attract long term capital inflowsJuly 2025 Analyst Calls & Reliable Intraday Trade Plans - BỘ NỘI VỤ
NeuroPace Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Panagora Asset Management Inc. Makes New $1.11 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
Will NeuroPace Inc. stock deliver consistent dividendsEarnings Growth Summary & Reliable Price Breakout Signals - Newser
1.64%
0.32%
자본화:
|
볼륨(24시간):